Caregivers track phosphorylated tau research by following plasma p-tau217 and p-tau231 dementia-risk findings and checking Lewy-body dementia trial finders. Phosphorylated tau means tau protein with added phosphate groups, a blood and spinal-fluid marker for Alzheimer's-type co-pathology.
Parkinson's disease dementia develops after established Parkinson's. It groups with dementia with Lewy bodies as Lewy body dementia, according to NINDS, so tau co-pathology work matters directly for these families NINDS Lewy Body Dementia page. Tracking this research helps caregivers separate near-term care planning from experimental tests.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What tau adds to Parkinson's dementia
- What the new blood-test study showed
- Where the limits sit for families
- How to follow trials and new studies
What tau adds to Parkinson's dementia
Tau and alpha-synuclein interact in Parkinson's. A 2026 Frontiers in Aging Neuroscience review links tau dysregulation and abnormal phosphorylation to that interaction.
It ties tau abnormalities most consistently to thinking problems and dementia, not to motor decline. A separate npj Parkinson's Disease study reported plasma p-tau217 sensitively detects amyloid-beta co-pathology in synuclein diseases including Parkinson's. That result helps explain mixed symptoms when memory loss overlaps Parkinson's changes.
What the new blood-test study showed
A prospective longitudinal study in npj Parkinson's Disease followed 123 Parkinson's patients and 40 controls for a mean 5.1 years. Among 109 patients without dementia at start, 35 progressed to dementia, or 32.1%.
Higher baseline plasma p-tau217 and p-tau231 predicted progression to Parkinson's dementia and earlier conversion, according to the Bioengineer.org summary of the 2026 study Bioengineer.org summary of the 2026 p-tau forecast study. The finding supports blood tests as risk-stratification tools, not as solo diagnoses.
Where the limits sit for families
Plasma p-tau217 alone was not clearly tied to early cognitive impairment in Parkinson's without dementia. The study authors call for larger multicenter studies before clinical use, as reported by Parkinson's News Today in 2026.
For caregivers, a high research value does not define current thinking ability. Use risk information for planning conversations and follow-up, not for labeling decline.
How to follow trials and new studies
Caregivers can track interventional work on ClinicalTrials.gov. Trial NCT02243982, for example, compares spinal-fluid tau, phospho-tau and FDDNP-PET imaging across controls, Parkinson's without dementia and Parkinson's dementia, as listed on ClinicalTrials.gov ClinicalTrials.gov entry for trial NCT02243982.
For new observational and support studies, NIA and the Michael J. Fox Foundation point caregivers to broader finders. Use these entry points:.
- NIA's Alzheimers.gov Clinical Trials Finder for Lewy-body dementia and caregiving studies
- Michael J. Fox Foundation Fox Trial Finder and PPMI biomarker program for Parkinson's blood-marker work
- Trial number, tau term, and location filters to narrow results and set a revisit date





